08.06.2021

BioAgilytix

Print this page
Forward this page

BOSTON, Massachusetts, June 8th 2021 – BioAgilytix, a leading bioanalytical laboratory specializing in large molecule bioanalysis, recently held a ribbon-cutting to celebrate the large-scale expansion of its leading-edge Boston laboratory. Located in the Cambridge, Massachusetts biopharma hub, the expanded CLIA-certified, CAP-accredited laboratory added 21-color flow cytometry and ddPCR, plus additional capacity for more qPCR, ADA/PK and biomarker testing to its already robust preclinical and clinical trials and diagnostic testing capabilities.

“With our expanded Boston lab, larger scientific team and new instrumentation, we continue to lead the field in helping our biopharma customers capitalize on these newest technologies for a powerful advantage in the analysis space,” said Dr. Linda Robbie, Vice President and General Manager, BioAgilytix Boston. “We pride ourselves on white glove, bespoke solutions that focus on the science. Our clients value our highly specialized expertise in designing assays that can lead them down the right pathways. At the end of the day, together we focus our abilities on enabling the best possible clinical outcomes for patients.”

 

With these expansions, BioAgilytix’s Boston lab doubled its square footage as well as its employee base. The team, comprised of some of the brightest scientists in the world with deep domain knowledge and industry experience, enables our clients to leverage this expertise to create an optimal bioanalytical testing plan that complements their drug development programs.

 

“The expansion of our Boston lab, paired with its exceptional location, enables us to foster vital academic, CRO and sponsor collaboration to positively impact patient outcomes,” shared Jim Datin, President and CEO of BioAgilytix. “This growth in our scientists and capacity, following the expansion of our Durham, NC lab earlier in the year, strengthens our mission to provide the most dependable, high-quality bioanalytical support and expertise, helping clients bring innovative therapies to patients more rapidly.”

    > press release 

 

About BioAgilytix

 

BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e., product release testing, stability testing, etc.). BioAgilytix also offers diagnostic testing services at its CLIA-certified, CAP-accredited Boston laboratory.

BioAgilytix’s team of highly experienced scientific and QA professionals ensures high-quality science, data integrity and regulatory compliance through all phases of clinical development. BioAgilytix is a trusted partner to many top global pharmaceutical and biotech companies. For more information, visit www.bioagilytix.com

Company: 

Cobepa S.A.

Cobepa S.A.
Rue de la Chancellerie 2, box 1
1000 Brussels
Belgium
Tel: 
+ 32 2 213 32 10
Fax: 
+ 32 2 513 17 02

Cobepa North America Inc.

Cobepa North America Inc.
Tower 49
12 East 49th Street
New York, NY 10017
United States
Tel: 
+1 (646) 679 5177

Ibel Beteiligungsberatung GmbH (Member of Cobepa Group)

Ibel Beteiligungsberatung GmbH
Theresienstrasse 1
80333 München
Germany
Tel: 
+32 2 213 32 10